In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ascendis Pharma A/S

http://www.ascendispharma.com/

Latest From Ascendis Pharma A/S

Four Orphan Drugs Get EU Approval Recommendation

The European Medicines Agency had a busy time at its meeting last week. It gave the green light to 11 products, four of which are for rare diseases including ANCA-associated vasculitis, and to a range of treatments for conditions as diverse as non-small cell lung cancer, smallpox, migraine, COPD, COVID-19 and obesity.

Europe Drug Review

Approval Delayed, But Janssen/Legend’s Cilta-Cel May Hit Market Just In Time

The US FDA has extended the user fee date by three months for the partners’ BCMA-targeting CAR-T therapy but its first-to-market rival is facing manufacturing challenges that limit access to treatment.

FDA Manufacturing

Finance Watch: Prepare For September IPOs To Rebound From August Slowdown

Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.

Financing Innovation

Keeping Track: US FDA Approves Korsuva, Skytrofa And Comirnaty, But Tecentriq Loses TNBC Indication

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Visen Pharmaceuticals
UsernamePublicRestriction

Register